OakChart

Indivior Pharmaceuticals Inc

INDVHealthcare·Drug Manufacturers - Specialty & Generic·USA·Mid·NASD·Nov 02 • 3:59 PM ET

28.150.00 (0.00%)
2026-11-11 16:33 CET
Market cap
3,587.14 USD m
Revenue, TTM
1,374.00 USD m
Net income, TTM
450.00 USD m
Free cash flow, TTM
25.96 USD m
EPS diluted, TTM
3.61
P/E
7.79
Compare

Price

INDV against its 20, 50 and 200-day averages
2050200beat
22.5025.0027.5030.0032.504.8M9.6MApr 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26INDVclose 28.1520-day 27.1350-day 27.30200-day 27.6928.15

15.3% under the 52-week high of 33.22 on 26 Jun 2026. Last 15 sessions, 14.6% high to low

Profile

INDV
52-week range, 57% of the way up
21.4833.22

Supernus, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of treatments for patients living with central nervous system (CNS) diseases. Its portfolio includes treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company was founded in 2005 and is headquartered in Rockville, MD.

Employees838
IPODec 29, 2014
Beta1.13
ATR, 14d0.98
Rel volume0.00
Short float7.87%
Insider own3.00%
Inst own97.23%

Snapshot

6 groups

Valuation

Index-
Market Cap5.97B
Enterprise Value6.17B
Income450.00M
Sales1.37B
Book/sh-0.51
Cash/sh1.44
Dividend Est.-
Dividend TTM-
Dividend Ex-DateNov 03, 2026
Dividend Gr. 3/5Y- -
Payout0.00%
Employees838
IPODec 29, 2014

Ratios

P/E7.79
Forward P/E7.25
PEG0.35
P/S4.35
P/B-
P/C19.58
P/FCF230.05
EV/EBITDA9.74
EV/Sales4.49
Quick Ratio0.50
Current Ratio0.62
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / No

Earnings

EPS (ttm)3.61
EPS next Y3.88
EPS next Q0.87
EPS this Y23.53%
EPS next Y25.75%
EPS next 5Y20.92%
EPS past 3/5Y- -
Sales past 3/5Y11.20% 13.88%
EPS Y/Y TTM265.06%
Sales Y/Y TTM16.44%
EPS Q/Q244.87%
Sales Q/Q13.38%
EarningsOct 29 BMO
EPS/Sales Surpr.24.45% 8.09%

Ownership

Insider Own3.00%
Insider Trans-1.13%
Inst Own97.23%
Inst Trans-
ROA32.75%
ROE-
ROIC-
Gross Margin85.08%
Oper. Margin45.05%
Profit Margin32.75%
SMA203.78%
SMA503.11%
SMA2001.68%
Trades-

Technical

Shs Outstand124.77M
Shs Float121.03M
Short Float7.87%
Short Ratio2.97
Short Interest9.52M
52W High33.22 -15.25%
52W Low21.48 31.07%
Volatility4.60% 3.65%
ATR (14)0.98
RSI (14)58.42
Beta1.13
Rel Volume0.00
Avg Volume3.21M
Volume0

Performance

Perf Week-
Perf Month0.61%
Perf Quarter-6.33%
Perf Half Y-5.22%
Perf YTD1.11%
Perf Year23.53%
Perf 3Y82.86%
Perf 5Y115.31%
Perf 10Y66.04%
Recom1.33
Target Price45.67
Prev Close28.15
Price28.15
Change %0.00%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Jun 18, 2026InitiatedBBarclaysOverweight$46+63.4%
Aug 06, 2025InitiatedHH.C. WainwrightBuy$27-4.1%
Jul 22, 2025ResumedJJefferiesBuy$20-29.0%
Jan 28, 2025InitiatedRRodman & RenshawBuy$16-43.2%
Jul 23, 2024InitiatedPPiper SandlerOverweight$22-21.8%
Apr 03, 2024InitiatedCCraig HallumBuy$37+31.4%
Jul 13, 2023InitiatedNNorthland CapitalOutperform$35+24.3%

Peers

Mkt cap
TickerCompanyMkt cap
ALKSAlkermes plc7.83B
AMRXAmneal Pharmaceuticals Inc7.56B
EBSEmergent Biosolutions Inc309.72M
SUPNSupernus Inc6.04B
COLLCollegium Pharmaceutical Inc753.19M
NBIXNeurocrine Biosciences Inc17.28B
PCRXPacira BioSciences Inc1.46B
AQSTAquestive Therapeutics Inc463.16M
ACADAcadia Pharmaceuticals Inc3.17B
HRMYHarmony Biosciences Holdings Inc1.97B

Insider trading

latest 14 of 16
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Anderson Woodrow DChief Accounting OfficerAug 27 '26Buy35.691,50053,53527,638Aug 27 04:00 PM
Anderson Woodrow DChief Accounting OfficerAug 05 '26Buy36.281,50054,42026,138Aug 05 04:52 PM
Heidbreder ChristianChief Scientific OfficerJul 10 '26Sale41.1418,586764,628209,337Jul 13 04:31 PM
Heidbreder ChristianOfficerJul 10 '26Proposed Sale41.1418,586764,628Jul 10 10:01 AM
Heidbreder ChristianChief Scientific OfficerJun 11 '26Sale38.0618,586707,383227,923Jun 12 04:10 PM
Heidbreder ChristianOfficerJun 11 '26Proposed Sale38.0618,586707,383Jun 11 11:20 AM
Preblick RyanChief Financial OfficerJun 08 '26Sale37.7036,0001,357,200284,751Jun 10 06:04 AM
Preblick RyanOfficerJun 08 '26Proposed Sale37.7036,0001,357,200Jun 08 01:58 PM
Ryan BarbaraDirectorMar 13 '26Buy31.0982495,724Mar 13 04:25 PM
Kingsley Stuart ADirectorMar 06 '26Buy31.8694029,9535,582Mar 11 09:54 AM
Ryan BarbaraDirectorMar 09 '26Buy32.56311,0095,716Mar 11 08:12 AM
Ryan BarbaraDirectorJan 05 '26Buy35.3977527,4291,963Jan 07 01:51 PM
Humphreys KeithDirectorJan 05 '26Buy35.3977527,4295,802Jan 07 01:50 PM
NINIVAGGI DANIEL ADirectorJan 05 '26Buy35.3977527,42916,923Jan 07 01:49 PM

News

latest 14 of 206
  • Indivior Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600 (PR Newswire)
  • MSG Rangers and Huron Consulting Group Set to Join S&P SmallCap 600 (PR Newswire)
  • Indivior Heads Into Q3 With Street Estimates Trailing Its Raised Revenue Outlook (Earnings Whispers)
  • Indivior to Report Third Quarter 2026 Financial Results (GlobeNewswire)
  • Loading…
  • Are LFCR, ITGR, FHB, INDV Obtaining Fair Deals for their Shareholders? (PR Newswire)
  • Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend (GlobeNewswire)
  • Indivior Shares Surge After Strong Quarterly Results and Higher 2026 Outlook (InvestorsHub) -6.60%
  • Supernus Shares Jump After Revenue Beat, Higher Guidance and Indivior Merger Announcement (InvestorsHub)
  • Supernus jumps premarket on merger deal; GameStop drops (Investing.com)
  • Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance (GlobeNewswire)
  • This Pharma Stock Eyes Entry As Opioid Addiction Specialist's Profits Surge 108% (Investor's Business Daily)
  • Indivior to Report Second Quarter 2026 Financial Results and Host Webcast (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-291.3201.0611.120356329.353
2026Q22026-08-031.1500.8690.984343306.234
2026Q12026-04-300.9600.6600.690317272.845
2025Q42026-02-260.8200.6740.816358305.625
2025Q32025-10-300.7200.4120.326314261.926
2025Q22025-07-310.5100.2600.143302244.54
2025Q12025-04-240.4100.2330.376266240.133
2024Q42025-02-200.3200.2230.160298259.784
2024Q32024-10-240.5400.4070.030307302.973
2024Q22024-07-250.4400.403-0.794299289.73
2024Q12024-04-250.3700.4150.339284299.752
2023Q42024-02-220.4300.3000.3802932762
2023Q32023-11-090.3400.340-0.980271270.52
2023Q22023-07-270.3900.2200.2732762551
2023Q12023-04-270.400-0.312253302.67-
2022Q42023-02-160.270--1.341241--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY1.1501.2920.887785801.97
2020FY0.4000.461-1.010647647.5
2021FY0.9000.7421.329791757.87
2022FY1.1601.087-0.381901898.75
2023FY1.5701.390-0.9421,0931,078
2024FY1.6601.6570.0531,1881,151
2025FY2.5002.3531.6401,2391,191
2026FY-3.088--1,694
2027FY-3.884--2,414
2028FY-4.420--2,582
2029FY-5.350--2,835
2030FY-5.930--2,986

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-11200532.36468596.71
2026Q4S2026-11-09400435.13331.5596.71
2026Q4S2026-11-02300381.27331.5468
2026Q4S2026-10-29200337.9331.5344.3
2026Q4S2026-10-17200337.9331.5344.3
2026Q4S2026-08-03220337.9331.5344.3
2026Q4S2026-07-31310321.17308.2331
2026Q4S2026-07-16410323.63308.2331
2026Q4S2026-07-14400322.38308.2331
2026Q4S2026-06-06430322.38308.2331
2026Q4S2026-05-12530316.9295331
2026Q4S2026-04-30540316.9295331
2026Q4S2026-04-17530305.86295312.9
2026Q4S2026-03-31520305.06295312.9

Estimate history

EPS, annual0.41.8310.887-1.011.329-0.381-0.9420.0531.6413.6127
Period201720182019202020212022202320242025TTM
EPS, quarterly0.030.160.3760.1430.3260.8160.690.9841.123
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual109310057856477919011093118812391374
Period201720182019202020212022202320242025TTM
Sales, quarterly307298266302314358317343356
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual144.293145.688146.158146.727140.488136.481137125125118
Period201720182019202020212022202320242025MRQ
Shares, quarterly129.575125125125125125122118118
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1,374.001,239.001,188.001,093.00901.00791.00647.00785.001,005.00
Cost of Goods Sold Incl. D&A205.00223.00211.00174.00172.00140.00109.00159.00141.00
Gross Profit1,169.001,016.00977.00919.00729.00651.00538.00626.00864.00
Selling, General and Administrative Excl. Other550.00658.00707.00685.00520.00464.00450.00424.00532.00
Research and Development33.0080.00107.00116.0072.0052.0040.0053.0067.00
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income619.00358.00270.00234.00209.00187.0088.00202.00332.00
Interest Expense18.0045.0041.0035.0029.0026.0026.0020.0031.00
Unusual Expense87.00105.00228.00401.00297.00-5.00244.0026.0040.00
Net Income Before Taxes538.00239.0020.00-149.00-95.00190.00-173.00180.00278.00
Income Taxes88.0029.0013.00-20.00-42.00-15.00-25.0046.003.00
Consolidated Net Income450.00210.007.00-129.00-53.00205.00-148.00134.00275.00
Net Income From Continuing Operations450.00210.007.00-129.00-53.00205.00-148.00134.00275.00
Net Income450.00210.007.00-129.00-53.00205.00-148.00134.00275.00
EPS (Recurring)4.192.211.251.111.111.310.161.012.02
EPS (Basic, Before Extraordinaries)3.721.680.05-0.94-0.381.41-1.010.921.89
EPS (Diluted)3.611.640.05-0.94-0.381.33-1.010.891.83
EBITDA633.00378.00298.00249.00230.00209.00114.00230.00348.00
Non-Operating Income (Expense)23.0031.0019.0052.0022.0024.009.0024.0017.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense25.8724.0019.0015.7512.968.916.482.4312.15
Price To Earnings Ratio7.967.96--14.289.54-2.202.72
Price To Sales Ratio3.183.711.391.913.453.361.660.501.01
Gross Margin85.0882.0082.2484.0880.9182.3083.1579.7585.97
Operating Margin45.0528.8922.7321.4123.2023.6413.6025.7333.03
Net Margin32.7516.950.59-11.80-5.8825.92-22.8717.0727.36
Shares Outstanding118.00125.00125.00137.00136.48140.49146.73146.16145.69
Market Capitalization3,587.143,587.141,208.191,618.802,303.541,880.35833.93294.85763.03

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue356.00343.00317.00358.00314.00302.00266.00298.00
Cost of Goods Sold Incl. D&A51.0050.0040.0064.0062.0052.0044.007.00
Gross Profit305.00293.00277.00294.00252.00250.00222.00291.00
Selling, General and Administrative Excl. Other119.00128.00131.00172.00153.00179.00154.00196.00
Research and Development0.007.009.0017.0020.0021.0022.0031.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income186.00165.00146.00122.0099.0071.0068.0095.00
Interest Expense2.002.007.006.0012.0015.0012.0013.00
Unusual Expense6.006.0027.0048.0056.000.001.0052.00
Net Income Before Taxes182.00160.00115.0081.0037.0062.0059.0036.00
Income Taxes45.0038.0026.00-21.00-5.0044.0011.0016.00
Consolidated Net Income137.00122.0089.00102.0042.0018.0047.0020.00
Net Income From Continuing Operations137.00122.0089.00102.0042.0018.0047.0020.00
Net Income137.00122.0089.00102.0042.0018.0047.0020.00
EPS (Recurring)1.161.020.841.080.630.140.380.45
EPS (Basic, Before Extraordinaries)1.161.030.720.820.340.140.380.16
EPS (Diluted)1.120.980.690.820.330.140.380.16
EBITDA188.00168.00150.00127.00104.0074.0073.0099.64
Non-Operating Income (Expense)4.003.003.0013.007.006.004.005.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.328.697.113.754.746.325.00-
Price To Earnings Ratio7.9616.1214.2427.7226.39---
Price To Sales Ratio3.183.823.053.622.641.581.021.31
Gross Margin85.6785.4287.3882.1280.2582.7883.4697.65
Operating Margin52.2548.1046.0634.0831.5323.5125.5631.88
Net Margin38.4835.5728.0828.4913.385.9617.676.71
Shares Outstanding118.00118.00122.00125.00125.00125.00125.00125.00
Market Capitalization3,587.143,972.122,950.783,473.552,334.091,426.98921.761,208.19

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments195.00320.00410.00893.001,102.00858.001,060.00924.00863.00
Short Term Receivables255.00287.00254.00225.00215.00219.00204.00318.00295.00
Inventories153.00167.00135.00114.0095.0093.0073.0078.0052.00
Other Current Assets49.0053.00467.0027.0032.0017.0023.009.0015.00
Total Current Assets652.00827.001,266.001,259.001,444.001,187.001,360.001,329.001,225.00
Net Property, Plant & Equipment170.00139.00124.0085.0095.00103.00107.0057.0054.00
Total Investments and Advances28.0027.0041.0098.000.000.000.000.000.00
Long-Term Note Receivable-------33.0015.00
Intangible Assets2.006.0013.0070.0082.0062.0072.0084.0092.00
Deferred Tax Assets326.00283.00293.00219.00105.0075.0040.0044.0058.00
Other Assets26.0040.0028.0038.00106.00104.0073.000.000.00
Total Assets1,204.001,322.001,765.001,769.001,832.001,531.001,652.001,547.001,444.00
Short Term Debt Incl. Current Port. of LT Debt39.0028.0012.0011.0011.0012.009.004.005.00
Accounts Payable48.0063.0039.0036.00573.00416.00499.00557.00473.00
Income Tax Payable2.007.008.009.007.0015.0039.0024.0041.00
Other Current Liabilities825.00826.001,231.00963.00213.00156.00195.00233.00335.00
Total Current Liabilities914.00924.001,290.001,019.00804.00599.00742.00818.00854.00
Long Term Debt312.00347.00271.00266.00275.00273.00284.00237.00477.00
Provision for Risks Charges0.000.000.005.0076.0051.00417.00424.00316.00
Deferred Tax Liabilities3.006.005.00------
Other Liabilities73.00382.00390.00428.00474.00526.000.002.000.00
Total Liabilities1,302.001,659.001,956.001,718.001,629.001,449.001,443.001,481.001,647.00
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-98.00-337.00-191.0051.00203.0082.00209.0066.00-203.00
Total Shareholders Equity-98.00-337.00-191.0051.00203.0082.00209.0066.00-203.00
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-98.00-337.00-191.0051.00203.0082.00209.0066.00-203.00
Total Liabilities & Stockholders Equity1,204.001,322.001,765.001,769.001,832.001,531.001,652.001,547.001,444.00
Book Value Per Share-0.78-2.70-1.390.371.440.561.430.45-1.41
Tangible Book Value Per Share-0.80-2.74-1.49-0.140.860.140.94-0.12-2.04
Full-Time Employees8381,0511,1649538857887969151,023
Price to Book Ratio-56.54-7.48-68.1010.249.2610.171.4111.56-41.60
Return on Assets16.610.45-7.30-2.9412.19-9.308.3818.394.37
Return on Equity--7.84-41.73143.86-101.7297.45--
Return on Invested Capital98.1370.00-161.25-16.7242.89-41.6927.1890.7621.17
Quick Ratio0.550.710.881.121.681.831.731.531.37
Current Ratio0.710.900.981.241.801.981.831.621.43

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income448.84210.007.00-129.00-85.00213.00-156.00178.00292.00
Depreciation13.7820.0028.0015.0021.0022.0026.0028.0016.00
Other Funds (Non Cash)68.4046.0040.00173.00-65.00-55.00-44.0024.00-34.00
Funds from Operations527.79230.0082.00-6.00-129.00180.00-174.00230.00274.00
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-437.37-257.00-46.00-294.00125.00173.00-19.00-79.0029.00
Cash from Operating Activities90.42-27.0036.00-300.00-4.00353.00-193.00151.00303.00
Capital Expenditures-64.45-67.00-31.00-53.00-6.00-34.00-4.00-7.00-41.00
Net Assets From Acquisitions0.000.000.00-129.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments1.011.00100.0084.00-218.000.000.000.000.00
Purchase of Investments-17.80-20.00-17.00-45.00-245.000.000.000.000.00
Sale Or Maturity of Investments18.8121.00117.00129.0027.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.003.001.0020.000.005.0037.00
Cash from Investing Activities-63.44-66.0069.00-95.00-223.00-14.00-4.00-2.00-4.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-301.65-9.00-170.00-30.00-88.00-100.001.000.003.00
Repurchase of Common Pref Stock-301.62-11.00-173.00-33.00-90.00-101.000.000.000.00
Sale of Common Pref Stock-0.032.003.003.002.001.001.000.003.00
Proceedsfrom Stock Options-0.032.003.003.002.001.001.000.003.00
Issuance or Reduction of Debt, Net0.00-17.0092.00-12.00-3.0014.00-4.00-4.00-240.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00-
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00-
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00-
Net Financing Active Other Cash Flow-15.95-4.00-24.00-22.000.000.000.000.000.00
Other Financing Activities Uses-21.94-4.00-24.00-22.000.000.000.000.000.00
Cash from Financing Activities-171.53-30.00-102.00-64.00-100.00-94.00-10.00-13.00-237.00
Exchange Rate Effect0.02-1.000.001.00-1.00-1.005.000.00-1.00
Net Change in Cash-145.56-124.003.00-458.00-328.00244.00-202.00136.0061.00
Free Cash Flow25.96-93.007.00-308.00-9.00349.00-197.00144.00292.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow168.49-236.17--7.62-2.733.47
Deferred Taxes & Investment Tax Credit--46.007.00-65.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments305.00222.00175.00195.00445.00510.00
Short Term Receivables286.00287.00285.00255.00272.00243.00
Inventories149.00150.00152.00153.00155.00149.00
Other Current Assets61.0068.0055.0049.0049.0048.00
Total Current Assets801.00725.00667.00652.00921.00951.00
Net Property, Plant & Equipment187.00183.00179.00170.00154.00152.00
Total Investments and Advances27.0027.0027.0028.0028.0027.00
Intangible Assets2.002.002.002.002.007.00
Deferred Tax Assets288.00271.00296.00326.00285.00270.00
Other Assets27.0024.0026.0026.0027.0044.00
Total Assets1,332.001,233.001,197.001,204.001,416.001,452.00
Short Term Debt Incl. Current Port. of LT Debt495.009.009.0039.0028.0029.00
Accounts Payable28.0030.0035.0048.0041.0050.00
Income Tax Payable63.0030.0026.002.004.0017.00
Other Current Liabilities715.00799.00709.00825.00892.00960.00
Total Current Liabilities1,301.00868.00779.00914.00965.001,056.00
Long Term Debt6.00500.00500.00312.00328.00337.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---3.00--
Other Liabilities85.0073.0062.0073.00330.00317.00
Total Liabilities1,392.001,441.001,341.001,302.001,623.001,710.00
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-60.00-208.00-144.00-98.00-207.00-257.00
Total Shareholders Equity-60.00-208.00-144.00-98.00-207.00-257.00
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-60.00-208.00-144.00-98.00-207.00-257.00
Total Liabilities & Stockholders Equity1,332.001,233.001,197.001,204.001,416.001,453.00
Book Value Per Share-0.51-1.76-1.18-0.78-1.66-2.06
Tangible Book Value Per Share-0.53-1.78-1.20-0.80-1.67-2.11
Full-Time Employees---838--
Price to Book Ratio-56.54-26.97-30.17-16.81-9.10-5.02
Return on Assets32.7526.4419.5216.538.825.96
Return on Invested Capital-41.7825.0047.6634.7122.50
Quick Ratio0.500.660.660.550.790.76
Current Ratio0.620.840.860.710.950.90

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income137.24121.5489.00101.0643.9419.92
Depreciation2.012.984.004.795.105.30
Other Funds (Non Cash)11.0714.8934.008.4426.653.33
Funds from Operations133.40164.31154.0076.0858.2139.81
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-36.1364.21-163.00-302.45-100.00126.11
Cash from Operating Activities97.28228.52-9.00-226.38-41.78165.91
Capital Expenditures-14.03-6.94-20.00-23.47-20.46-18.68
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-1.00-0.001.001.010.00-1.00
Purchase of Investments-4.01-2.98-5.00-5.81-3.05-6.33
Sale Or Maturity of Investments3.012.986.006.823.055.33
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-14.03-7.94-19.00-22.46-20.46-18.68
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.46-175.35-126.000.161.06-0.30
Repurchase of Common Pref Stock-0.46-175.35-126.000.190.03-0.33
Sale of Common Pref Stock0.000.000.00-0.031.020.03
Proceedsfrom Stock Options0.000.000.00-0.031.020.03
Issuance or Reduction of Debt, Net0.23-0.33151.00-4.84-4.08-4.24
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.972.03-18.00-0.960.01-0.09
Other Financing Activities Uses-0.030.05-21.00-0.960.01-0.09
Cash from Financing Activities-0.25-172.647.00-5.64-3.01-4.62
Exchange Rate Effect0.000.000.000.02-2.06-
Net Change in Cash82.9947.94-21.00-255.49-65.26142.61
Free Cash Flow83.24221.58-29.00-249.87-62.24148.26
Price to Free Cash Flow168.49---23.129.36

Revenue breakdown

Total Pharmaceutical Preparations revenue2024: 1.19B 2025: 1.24B
Consolidation, Policy2024: 1.00M
Non-US2024: 179.00M 2025: 186.00M
United States2024: 1.01B 2025: 1.05B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.87%9.5M121.0M3.14M
2026-10-157.78%9.4M121.0M2.25M
2026-09-308.60%10.4M121.0M2.03M
2026-09-159.23%11.2M121.0M2.09M
2026-08-319.36%11.3M120.8M2.04M
2026-08-148.64%10.4M120.9M1.98M
2026-07-319.70%10.9M112.1M1.90M
2026-07-1510.06%11.3M112.1M1.97M
2026-06-309.62%10.8M112.1M1.98M
2026-06-1510.69%11.9M110.9M2.18M
2026-05-2911.23%12.7M112.7M2.57M
2026-05-1512.18%13.7M112.7M2.65M
2026-04-3011.04%12.8M116.2M2.45M
2026-04-1511.99%13.9M116.2M2.43M
2026-03-3111.09%13.4M120.7M2.53M
2026-03-1310.10%12.2M120.7M2.58M
2026-02-278.30%10.0M120.7M2.35M
2026-02-139.17%11.1M120.7M2.28M
2026-01-3010.81%12.2M113.1M2.46M
2026-01-1510.34%11.7M113.1M2.54M

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-043Initial statement of beneficial ownership of securities2026-11-02SEC
2026-11-043Initial statement of beneficial ownership of securities2026-11-02SEC
2026-11-043Initial statement of beneficial ownership of securities2026-11-02SEC
2026-11-043Initial statement of beneficial ownership of securities2026-11-02SEC
2026-11-043Initial statement of beneficial ownership of securities2026-11-02SEC
2026-11-043Initial statement of beneficial ownership of securities2026-11-02SEC
2026-11-043Initial statement of beneficial ownership of securities2026-11-02SEC
2026-11-043Initial statement of beneficial ownership of securities2026-11-02SEC
2026-11-043Initial statement of beneficial ownership of securities2026-11-02SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-11-028-KCurrent report2026-11-02SEC
2026-10-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-29425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-298-KCurrent report2026-10-29SEC
2026-10-158-KCurrent report2026-10-15SEC
2026-10-06425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-068-KCurrent report2026-10-06SEC
2026-09-30SCHEDULE 13GSEC
2026-09-17425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-09-178-KCurrent report2026-09-16SEC
2026-09-158-KCurrent report2026-09-09SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08107.96K200
2026-0700764.63K1
2026-06002.06M2
2026-050000
2026-040000
2026-0331.21K300
2026-020000
2026-01172.40K500
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.15.00%
VANGUARD PORTFOLIO MANAGEMENT LLC6.07%
OAKTREE CAPITAL MANAGEMENT LP4.91%
VANGUARD CAPITAL MANAGEMENT LLC4.40%
STATE STREET CORP4.00%
FULLER & THALER ASSET MANAGEMENT, INC.3.70%
Two Seas Capital LP2.94%
Assenagon Asset Management S.A.2.84%
MORGAN STANLEY2.72%
FRANKLIN RESOURCES INC2.66%

Funds

Fund% owned
Franklin Convertible Securities Fund20.76%
Virtus Income & Growth Fund5.97%
iShares Core S&P Small-Cap ETF5.89%
Virtus Convertible Fund5.63%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.10%
iShares Russell 2000 ETF2.47%
VANGUARD SMALL-CAP INDEX FUND2.24%
FULLERTHALER BEHAVIORAL SMALL-CAP GROWTH1.73%
Advent Convertible & Income Fund1.61%
Virtus Convertible & Income Fund1.49%

OakChart. INDV. Cached 15 minutes.